Nuformix (LON:NFX) Issues Quarterly Earnings Results

Nuformix (LON:NFX) posted its earnings results on Tuesday. The company reported GBX (0.04) EPS for the quarter, Digital Look Earnings reports.

Nuformix Stock Performance

LON NFX traded down GBX 0.04 on Tuesday, reaching GBX 0.23. 116,662,734 shares of the stock traded hands, compared to its average volume of 28,102,768. The company has a market cap of £4.85 million, a price-to-earnings ratio of -0.59 and a beta of 1.22. Nuformix has a 12 month low of GBX 0.01 and a 12 month high of GBX 0.56. The company has a fifty day moving average price of GBX 0.28 and a 200-day moving average price of GBX 0.21.

About Nuformix

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.